Lassa Fever - Pipeline Review, H1 2016

  • ID: 3775419
  • Report
  • 54 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • SIGA Technologies, Inc.
  • MORE
Lassa Fever - Pipeline Review, H1 2016

Summary

‘Lassa Fever - Pipeline Review, H1 2016’, provides an overview of the Lassa Fever pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lassa Fever
- The report reviews pipeline therapeutics for Lassa Fever by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Lassa Fever therapeutics and enlists all their major and minor projects
- The report assesses Lassa Fever therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Lassa Fever

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Lassa Fever
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lassa Fever pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • SIGA Technologies, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Lassa Fever Overview

Therapeutics Development

Pipeline Products for Lassa Fever - Overview

Pipeline Products for Lassa Fever - Comparative Analysis

Lassa Fever - Therapeutics under Development by Companies

Lassa Fever - Therapeutics under Investigation by Universities/Institutes

Lassa Fever - Pipeline Products Glance

Early Stage Products

Lassa Fever - Products under Development by Companies

Lassa Fever - Products under Investigation by Universities/Institutes

Lassa Fever - Companies Involved in Therapeutics Development

Arno Therapeutics, Inc.

Celgene Corporation

Etubics Corporation

Kineta, Inc.

Profectus BioSciences, Inc.

SIGA Technologies, Inc.

Lassa Fever - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AR-12 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CC-11050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DEF-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FBH-003 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FDX-000 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KIN-1400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine 1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lassa fever vaccine 2 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LHF-535 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Lassa Fever - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies for Viral Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ST-193 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Lassa Fever - Dormant Projects

Lassa Fever - Product Development Milestones

Featured News & Press Releases

May 05, 2016: Kineta Receives Wellcome Trust Award to Advance Novel Therapeutic for Lassa Fever into Clinical Trials

Apr 22, 2016: Kineta Presents Promising New Data on Novel Lassa Fever Antiviral and Broad Spectrum Innate Immune Antivirals

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Lassa Fever, H1 2016

Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Lassa Fever - Pipeline by Arno Therapeutics, Inc., H1 2016

Lassa Fever - Pipeline by Celgene Corporation, H1 2016

Lassa Fever - Pipeline by Etubics Corporation, H1 2016

Lassa Fever - Pipeline by Kineta, Inc., H1 2016

Lassa Fever - Pipeline by Profectus BioSciences, Inc., H1 2016

Lassa Fever - Pipeline by SIGA Technologies, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Lassa Fever - Dormant Projects, H1 2016

List of Figures

Number of Products under Development for Lassa Fever, H1 2016

Number of Products under Development for Lassa Fever - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Arno Therapeutics, Inc.
  • Celgene Corporation
  • Etubics Corporation
  • Kineta, Inc.
  • SIGA Technologies, Inc.
  • MORE
Lassa Fever Lassa fever is an acute viral hemorrhagic illness caused by Lassa virus, a member of the arenavirus family of viruses. It is transmitted to humans from contacts with food or household items contaminated with rodent excreta. Symptoms include fever, headache, chills, back pain, weight loss, swollen neck, rashes and bleeding.

Lassa Fever pipeline therapeutics constitutes close to 15 molecules. Out of which approximately 14 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Preclinical and Discovery stages are 8 and 6 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Our latest report Lassa Fever – Pipeline Review, H1 2016, outlays comprehensive information on the therapeutics under development for Lassa Fever, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews of key players involved in therapeutic development for Lassa Fever and features dormant and discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
Arno Therapeutics, Inc.
Celgene Corporation
Etubics Corporation
Kineta, Inc.
Profectus BioSciences, Inc.
SIGA Technologies, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll